Date and time of publication on KAP: 02.04.2025 17:43:50 https://www.kap.org.tr/en/Bildirim/1416505



KAMUYU AYDINLATMA PLATFORMU

# BİOTREND ÇEVRE VE ENERJİ YATIRIMLARI A.Ş. Notification Regarding General Assembly



# **Notification Regarding General Assembly**

Summary Info	Ordinary General Assembly Meeting Results
Update Notification Flag	Yes
Correction Notification Flag	No
Postponed Notification Flag	No

# General Assembly Invitation

General Assembly Type	Annual
Begining of The Fiscal Period	01.01.2024
Ending Date Of The Fiscal Period	31.12.2024
Decision Date	06.03.2025
General Assembly Date	02.04.2025
General Assembly Time	13:30
Record Date (Deadline For Participation In The General Assembly)	01.04.2025
Country	Turkey
City	İSTANBUL
District	BEYKOZ
Address	Kavacık Mahallesi Ertürk Sokak No:3/1 İç Kapı No:1 Beykoz İSTANBUL

#### Agenda Items

1 - Opening and election of the Meeting Chairperson, authorizing the Meeting Chairperson to sign the minutes of meeting,

2 - Reading, discussion, and approval of the Board of Directors' Annual Report for the 2024 operating period,

3 - Reading, discussion, and submitting for approval, of the summary of the Independent Auditor's Report prepared by the Independent Audit Firm for the 2024 operating period,

4 - Reading, discussion, and submitting for approval, of the Financial Statements for the 2024 operating period,

5 - Making a resolution on release of the members of the Board of Directors on an individual basis for their activities and transactions for 2024,

6 - Discussing, and making a resolution on, the proposal of the Board of Directors regarding the profit/loss for 2024,

7 - Informing the General Assembly on related party transactions conducted in 2024,

8 - Submitting the amendments made by the Board of Directors decision dated 22.01.2025 to the 'Remuneration Policy' prepared by the Board of Directors in order to comply with the Capital Markets Board's Corporate Governance Communiqué II-17.1 and approved at the Extraordinary General Assembly held on 25.02.2021 for the information of the General Assembly and obtaining their opinions,

9 - Submitting of the changes made in the membership of the Board of Directors during the year pursuant to Article 363 of the Turkish Commercial Code to the approval of the General Assembly,

10 - Election of the members of the Board of Directors and determination of their terms of office, determination of the attendance fees to be paid to the members,

11 - Informing the shareholders about the payments made within the scope of the "Remuneration Policy" for the members of the Board of Directors and senior executives in accordance with the Corporate Governance Principles,

12 - Submitting of the independent audit firm appointed by the Board of Directors for 2025 upon proposal by the Audit Committee, for the approval of the General Assembly,

13 - Informing the General Assembly about the share buy-back transactions initiated by the Board of Directors' resolution dated February 14, 2023, within the framework of the Capital Markets Board's ("CMB") Communiqué No. II-22.1 on Buy-Back Shares and the announcement made on February 14, 2023,

14 - Within the scope of the Capital Markets Board's Communiqué No. II-22.1 on Buy-Back Shares, submission of the 'Share Buy-Back Programme' to be prepared until the date of the general assembly for the approval of the general assembly and discussion and resolution of the authorisation of the board of directors within the scope of the 'Share Buy-Back Programme.

15 - Discussing the amendment text of the Articles of Association regarding the amendment of Article 6 of the Company's Articles of Association and submitting it to the approval of the General Assembly,

16 - Informing the General Assembly within the scope of Principle No. 1.3.6 of the Capital Markets Board's Corporate Governance Communiqué No. II-17.1,

17 - Informing the General Assembly about the guarantees, pledges and mortgages given by the Company in favour of third parties in 2024 in accordance with the Capital Markets Board regulations,

18 - Informing the shareholders about the donations and aids made by the Company to foundations and associations for social relief purposes in 2024 and setting an upper limit for donations to be made in 2025 in accordance with the Capital Markets Board regulations,

19 - Authorizing the members of the Board of Directors to perform the transactions specified in Articles 395 and 396 of the Turkish Commercial Code and informing the General Assembly about the transactions carried out within this scope in 2024 in line with the Corporate Governance Principles,

### Corporate Actions Involved In Agenda

#### Dividend Payment

Authorized Capital

General Assembly Results	
Was The General Assembly Meeting Executed?	Yes
General Assembly Results	The Ordinary General Assembly meeting of our company was held on 02.04.2025 at the headquarters of our company. The Minutes of the Ordinary General Assembly Meeting and the List of Attendants, including the decisions taken at the Ordinary General Assembly Meeting, are attached hereto.

Decisions Regarding Corporate Actions		
Dividend Payment	Discussed	
Authorized Capital	Accepted	
General Assembly Result Documents		
Appendix: 1	BIOEN 2024 Annual General Assembly Meeting Minute.pdf - Minute	
Appendix: 2	Biotrend Olağan Genel Kurul Hazirun.pdf - List of Attendants	
Appendix: 3	Biotrend- Olağan Genel Kurul Toplantı Tutanağı.pdf - Minute	

# Additional Explanations

English translation of this disclosure is attached hereto. In the case of discrepancies between the Turkish and English versions of this disclosure, the Turkish version shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in "Material Events Communiqué" of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we're personally liable for the disclosures.